@article{cca014ead0ae4ecfb66ff20d9e8c80fe,
title = "Age cutoff for epstein-barr virus-positive diffuse large B-cell lymphoma - is it necessary?",
abstract = "Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (EBV+ DLBCL-e) is a molecularly distinct variant of DLBCL, characterized by a monoclonal B-cell proliferation that occurs in patients >50 years of age without a history or clinicopathologic evidence of immunodeficiency. However, patients with EBV+ DLBCL younger than 50-years-old also exist in Western countries. We evaluated the clinicopathologic, immunophenotypic and genetic features in Cacausian patients with EBV+ DLBCL who are ≤50 years of age and compared this patient group to patients who are >50 years. In patients who are ≤50 years, less frequent expression of BCL6 and a trend of more frequent expression of CD30 and pSTAT3 were found in patients with EBV+ DLBCL. In patients who are >50 years, common expression of CD30, p50, pSTAT3 and less frequent expression of BCL6 were observed. Older patients also more commonly had a poor performance status (ECOG≥2). Comparing EBV+ DLBCL patients in ≤50 years versus >50 years, both groups had similar clinicopathologic, immunophenotypic and genetic features. Gene expression profiling, microRNA profiling and treatment outcome of the younger patients with EBV+ DLBCL was not distinctive from tumors in older patients. Based on our data, we suggest that the arbitrary age cutoff for EBV+ DLBCL is unnecessary and should be eliminated in the WHO lymphoma classification scheme.",
keywords = "DLBCL, EBV, Elderly, Gene expression profiling",
author = "Ok, {Chi Young} and Qing Ye and Ling Li and Manyam, {Ganiraju C.} and Lijuan Deng and Goswami, {Rashmi R.} and Xiaoxiao Wang and Santiago Montes-Moreno and Carlo Visco and Alexandar Tzankov and Karen Dybkaer and Li Zhang and Jeremy Abramson and Sohani, {Aliyah R.} and April Chiu and Attilio Orazi and Youli Zu and Govind Bhagat and Richards, {Kristy L.} and Hsi, {Eric D.} and Choi, {William W.L.} and {van Krieken}, {J. Han} and Jooryung Huh and Maurilio Ponzoni and Ferreri, {Andr{\'e}s J.M.} and Shanxiang Zhang and Parsons, {Ben M.} and Mina Xu and M{\o}ller, {Michael B.} and Winter, {Jane N.} and Piris, {Miguel A.} and Xu-Monette, {Zijun Y.} and Medeiros, {L. Jeffrey} and Young, {Ken H.}",
note = "Funding Information: This study is supported by the National Cancer Institute and National Institutes of Health grants (R01CA138688 and R01CA187415, K.H.Y). CYO is the recipient of the advanced molecular pathology fellowship and hematopathology research awards; ZYXM is the recipient of the Harold C. and Mary L. Daily Endowment Fellowships and Shannon Timmins Fellowship for Leukemia Research Award. GM is supported by a grant from the Michael and Susan Dell Foundation. KHY is supported by The University of Texas MD Anderson Cancer Center Institutional Research Grant Award, an MD Anderson Lymphoma Specialized Programs of Research Excellence (SPORE) Research Development Program Award, an MD Anderson Myeloma SPORE Research Development Program Award, MD Anderson Collaborative Research Funds with High-Throughput Molecular Diagnostics, Gilead Pharmaceutical, Adaptive Biotechnology, and Roche Molecular Systems. This work was also partially supported by National Cancer Institute and National Institutes of Health grants (P50CA136411 and P50CA142509), and by the MD Anderson Cancer Center Support Grant CA016672.",
year = "2015",
month = jan,
day = "1",
language = "English (US)",
volume = "6",
pages = "13935--13946",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "16",
}
